Cited by 28Retinal Development and DisordersRetinal Diseases and TreatmentsPluripotent Stem Cells Research

Stem cell-based therapy for diseases of the retinal pigment epithelium: from bench to bedside

Sachdeva, Mira M., Eliott, Dean·2016·Seminars in Ophthalmology

Abstract

Age-related macular degeneration (AMD) represents a leading cause of blindness in the elderly, and Stargardt's macular dystrophy (SMD) is the most common form of juvenile-onset macular degeneration. Dry AMD and SMD share an underlying pathophysiology, namely dysfunction and ultimately loss of the retinal pigment epithelium (RPE), suggesting that RPE transplantation may offer a potential treatment strategy for both patient populations. Stem cells have emerged as a promising source of replacement RPE. During the past 15 years, extraordinary strides have been made in the identification, characterization, and differentiation of stem cells. Recently, this large body of basic science and preclinical research has been translated to patient care with the publication of results from Phase 1/2 trials demonstrating safety of transplantation of human embryonic stem cell (hESC)-derived RPE into patients with AMD and SMD. While significant challenges remain before dry AMD and SMD become treatable diseases, the goal has become more tangible.

Integrity signals

Registry

Crossref · 10.3109/08820538.2015.1115253

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sachdeva, M. M., & Eliott, D.
Affiliations
Massachusetts Eye and Ear Infirmary (US)
Corresponding author
Sachdeva, Mira M.
Venue
Seminars in Ophthalmology
Published
2016-03-03
Volume
31
Issue
1-2
Pages
25-29
ISSN
  • 0882-0538 (ISSN-L)
  • 1744-5205
OpenAlex
W2294783182
Cited by
28
References
39
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 2 · 2017: 5
FWCI
0.27
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
stem cell therapy, retinal pigment epithelium, age-related macular degeneration, RPE transplantation, human embryonic stem cells, stem cell differentiation, clinical trials, dry age-related macular degeneration, macular degeneration
MeSH terms
Human Embryonic Stem Cells, Stargardt Disease, Humans, Macular Degeneration, Stem Cell Transplantation, Retinal Pigment Epithelium, Geographic Atrophy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review